NHMRC caught up with Professor Andrew Lloyd from The University of New South Wales who develops vaccines for Hepatitis C, which effects 750,000 Australians. Find out how his research is not only helping treat Hepatitis C but working on prevention strategies.
[Music plays and an image of a Professor Andrew Lloyd and a male colleague appears on screen]
Professor Andrew Lloyd: My area of particular research interest is Hepatitis C vaccine development.
[Image changes to show Professor Andrew Lloyd, UNSW Sydney, seated and talking to the camera]
Hepatitis C affects a quarter of a million Australians and it’s largely socially disadvantaged individuals,
[Image changes to show Profess Andrew Lloyd and a male colleague standing together and talking]
hence my interest is into not only develop good treatments, but also prevention strategy for that group.
[Image changes to show Professor Andrew Lloyd and a female colleague standing together and talking in a laboratory type setting]
There are no funding agencies, of any sort, with an interest in Hepatitis C. NHRMC’s absolutely critical for my research agenda,
[Image changes back to show Professor Andrew Lloyd, seated and talking to the camera]
it has been since I was very first funded several decades ago for projects and programs and partnerships to develop that research agenda.
[Image changes to show Professor Andrew Lloyd standing in a laboratory and smiling at the camera]
it’s really totally NHMRC that makes this research possible.
[Music plays and NHMRC logo appears on screen with text beside it: Building a Healthier Australia]
End of transcript.